FN2 Earnings Intelligence
Neurocrine Biosciences, Inc. ratios
Neurocrine Biosciences, Inc. (NBIX) Ratios (annual) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $340.8 | $262.9 | $251.1 | $233 | $713 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $1,133.5 | $1,488.7 | $1,887.1 | $2,355.3 | $2,860.5 |
| % Growth | 8.4% | 31.3% | 26.8% | 24.8% | 21.4% |
| Gross Profit | - | $1,465.5 | $1,847.4 | $2,321.3 | $2,808.4 |
| % Margin | - | 98.4% | 97.9% | 98.6% | 98.2% |
| EBITDA | $113.4 | $264.1 | $268.7 | $594 | $645.1 |
| % Margin | 10.0% | 17.7% | 14.2% | 25.2% | 22.6% |
| Net Income | $89.6 | $154.5 | $249.7 | $341.3 | $478.6 |
| % Margin | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% |
| Diluted EPS | $0.92 | $1.56 | $2.47 | $3.29 | $4.67 |
| % Growth | -77.9% | 69.6% | 58.3% | 33.2% | 41.9% |
| Operating Cash Flow | $256.5 | $339.4 | $389.9 | $595.4 | $782.7 |
| CapEx | $23.4 | $16.5 | $28.3 | $38.2 | $34 |
| Free Cash Flow | $233.1 | $322.9 | $361.6 | $557.2 | $748.7 |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue | $1,133.5 | $1,488.7 | $1,887.1 | $2,355.3 | $2,860.5 |
| Gross Profit | - | $1,465.5 | $1,847.4 | $2,321.3 | $2,808.4 |
| EBITDA | $113.4 | $264.1 | $268.7 | $594 | $645.1 |
| Net Income | $89.6 | $154.5 | $249.7 | $341.3 | $478.6 |
| Diluted EPS | $0.92 | $1.56 | $2.47 | $3.29 | $4.67 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $340.8 | $262.9 | $251.1 | $233 | $713 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $256.5 | $339.4 | $389.9 | $595.4 | $782.7 |
| Capital Expenditure | $23.4 | $16.5 | $28.3 | $38.2 | $34 |
| Free Cash Flow | $233.1 | $322.9 | $361.6 | $557.2 | $748.7 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 8.4% | 31.3% | 26.8% | 24.8% | 21.4% |
| Gross Margin | - | 98.4% | 97.9% | 98.6% | 98.2% |
| EBITDA Margin | 10.0% | 17.7% | 14.2% | 25.2% | 22.6% |
| Net Margin | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% |
| FCF Margin | 20.6% | 21.7% | 19.2% | 23.7% | 26.2% |
| Diluted EPS Growth | -77.9% | 69.6% | 58.3% | 33.2% | 41.9% |
Get the NBIX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.